News und Analysen
![DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
![DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
![Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
![Lonza Delivers Strong 2021 performance with 20% CER Sales Growth](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
![DGAP-News: Abivax Finanzkalender 2022](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax Finanzkalender 2022
DGAP-News: Abivax Finanzkalender 2022
![DGAP-News: Abivax 2022 Financial Communication Calendar](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax 2022 Financial Communication Calendar
DGAP-News: Abivax 2022 Financial Communication Calendar
![DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
![DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
![DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
![DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
![DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
![DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
![DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
DGAP-Adhoc: Eckert & Ziegler unterzeichnet exklusiven Liefervertrag für Ytterbium-176
![DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
DGAP-Adhoc: Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
![Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
![DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
![DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
![DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
![DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
![DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
![DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis